Head and Neck Cancer Market is estimated to be US$ 2.9 Billion by 2034 with a CAGR of 5.40%during the forecast period

Head and Neck Cancers refers to group of Cancer which generates tissue in head and neck region. “Squamous cell carcinoma” contributes in 90% of the head and neck cancer and makes up the moist surface in head, neck & mouth region. The body parts affected due to differentiation of these cancerous cells are oral cavity and pharynx. Cancers in larynx are results of large alcohol abuse, huge consumption of tobacco or both. Whereas in pharynx cancers are mainly caused due to human papilloma virus (HPV). As of 2020, United States larynx of America alone accounts for 4% of total squamous cell carcinomas and by 2023 it is estimated that near to sixty-seven thousand people will be diagnosed.

A progressive rise in head and neck cancer cases has been observed in recent years, and increased societal understanding of the causes—tobacco use and alcohol consumption—has made it possible to comprehend how to stop the course of neoplastic disease. However, a sizable population is afflicted, and a recent trend has shown that many of them prefer non-surgical treatments like chemotherapy, immunosuppressive medications, and targeted therapy to surgical treatments. This is the key factor driving the Head and neck cancer market ahead.Head and Neck Cancer Market was valued at US$ 1.8 Billion in 2024 and is projected to grow at a CAGR of 5.40% to reach US$ 2.9 Billion by 2034.

The report “Head and Neck Cancer Market, By Drug Class (EGFR Inhibitors, Mitotic, Inhibitors, Anti-PD-1 Monoclonal Antibodies, and Others (Docetaxel, fluorouracil)), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and E-commerce), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa)- Trends, Analysis and Forecast till 2034”

 Key Highlights:

• In January 2023, Alkem oncology has announced the launch of “Cetuxa” world’s first biosimilar of cetuximab a monoclonal antibody approved by drug controller general of India (DGCI). Cetuxa aims to bring accessibility & affordability in treatment of head and neck cancer in India.
• In April 2023, Eisai helps build a head and neck cancer community through interactive stories. Working in partnership with head and neck alliance they support for people with oral, head and neck cancer. The focal point of the campaign, MadeOfMore.com, offers interactive artwork that vividly illustrates the experiences of actual people who have been touched by this broad group of malignancies, which receive little public attention yet will result in about 67,000 additional diagnoses in the United States in 2023.
• In April 2023, new findings to support novel combination treatment for head and neck cancer by Yale Cancer Center. The results of the studies conducted states that combined AURKA and WEE1 inhibition as a novel and effective treatment for patients with Head and Neck Cancer
• In July 2022, World’s first research Centre for recurrent head and neck cancer launched by Royal Marsden Cancer Charity funding. To accelerate research and improve patient outcomes.  To advance the study of the disease, the International Centre for Recurrent Head & Neck Cancer (IReC) brings together a group of top-tier clinicians and researchers. To enhance patient outcomes in the UK and elsewhere, IReC also intends to establish worldwide standards in the curative treatment, palliative care, and supportive care of recurrent head and neck cancer.

Analyst View:

The acceptance of chemotherapy, targeted therapy and immunosuppressive is increasing and simultaneously approval of drugs such as cetuximab, pembrolizumab & nivolumab which are used for targeted therapy and increase in cisplatin usage has seen in chemotherapy. These drugs are known for their cost affordability and easy accessibility and also some important market drivers include the rising incidence of a variety of HNCs as well as the ageing population. Since they are less expensive and more exact to approach than surgery, improvements in the detection and treatment of head and neck cancer (HNC) are predicted to drive Head and Neck Cancer Market growth.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on Head and Neck cancer market, By Drug Class (EGFR Inhibitors, Mitotic, Inhibitors, Anti-PD-1 Monoclonal Antibodies, and Others (Docetaxel, fluorouracil)), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and E-commerce), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa)- Trends, Analysis and Forecast till 2034”

Key Market Insights from the report:

Head and Neck Cancer Market was valued at US$ 1.8 Billion in 2024 and is projected to grow at a CAGR of 5.40% to reach US$ 2.9 Billion by 2034.The Head and neck cancer is segmented based on Drug Class, distribution channel and by region.

• Based on drug class, Head and neck cancer is segmented into EGFR Inhibitor, Mitotic Inhibitor Anti-PD-1 Monoclonal Antibodies and Docetaxel, fluorouracil
• Based on Distribution channel, Head and neck cancer is segmented into Hospitals Pharmacies, Retail Pharmacies, and E-commerce
• By Region, the Head and neck cancer is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Head and Neck Cancer Market:

The prominent players operating in the Head and neck cancer includes, Sanofi S.A., Pfizer Inc., Eli Lilly and Company, MERCK, Bristol-Myers Squibb Company, Bayer AG, Galera Therapeutics Inc., Fresenius Kabi AG, Teva Pharmaceuticals Industries Limited, and AstraZeneca PLC.

To know more

Contact Us:

Sales

Prophecy Market Insights

U.S.  1 860 531 2574

RoW: 917775049802

Email- [email protected]

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com